XBiotech Inc. (NASDAQ:XBIT - Get Free Report) shares passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.87 and traded as low as $2.81. XBiotech shares last traded at $2.89, with a volume of 31,271 shares trading hands.
XBiotech Stock Up 8.4%
The company has a market cap of $90.86 million, a PE ratio of -2.31 and a beta of 0.98. The firm has a 50 day simple moving average of $2.88 and a 200-day simple moving average of $3.18.
XBiotech (NASDAQ:XBIT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter.
Institutional Investors Weigh In On XBiotech
Institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG acquired a new stake in XBiotech in the fourth quarter worth about $120,000. Northern Trust Corp boosted its holdings in XBiotech by 15.2% in the fourth quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company's stock worth $835,000 after acquiring an additional 27,909 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in XBiotech by 68.2% in the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock worth $58,000 after acquiring an additional 5,930 shares in the last quarter. Barclays PLC boosted its holdings in XBiotech by 13.9% in the fourth quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock worth $119,000 after acquiring an additional 3,661 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in XBiotech by 7.5% in the fourth quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company's stock worth $360,000 after acquiring an additional 6,328 shares in the last quarter. Institutional investors and hedge funds own 55.70% of the company's stock.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Read More
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
